Stockscreener 앱 받기
9.28
10.34%
-1.07
전일 마감가:
$10.35
열려 있는:
$10.38
하루 거래량:
31.23M
Relative Volume:
1.53
시가총액:
$3.63B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-5.9871
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
-11.87%
1개월 성능:
+34.88%
6개월 성능:
+21.78%
1년 성능:
-24.98%
1일 변동 폭
$9.15
$10.60
1주일 범위
$9.15
$12.36
52주 변동 폭
$5.60
$15.74
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
9.28 | 3.63B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite? - MSN
Top Biotech Stocks To ConsiderFebruary 20th - MarketBeat
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite? - MarketBeat
Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Biotech Stocks Worth WatchingFebruary 15th - MarketBeat
Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025 - MSN
Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH Tumult - MedCity News
Backed by Recursion CEO, Altitude Lab venture aims to fill gap from NIH cuts - MM+M Online
10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey
Recursion CEO launches pre-seed fund in response to NIH cuts - BioPharma Dive
Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City - The Manila Times
Can This New Biotech Fund Save 1,500 Startups Hit by SBIR Changes? - StockTitan
Could this Nvidia-backed growth stock be a millionaire-maker at $10? - Yahoo Finance UK
Recursion CEO: Publicly funded research built the biopharma industry. Now it needs our help - STAT
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday - MSN
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 - MSN
5 Stocks Jensen Huang’s Company is Betting On - Insider Monkey
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock - MSN
Altitude Lab's Startup Portfolio Hits $154M Milestone: Inside the Biotech Incubator's Success Story - StockTitan
25 Top AI Stocks That Could Boost Your Portfolio - The Motley Fool
SoftBank Joins Nvidia In Backing Recursion Pharma, Retail Traders Rally Behind Stock Surge - NewsBreak
Nvidia-Backed Recursion Pharma Hits 3-Week High, Sparks Retail Buzz Amid Broader AI Hype - MSN
Best Biotech Stocks To Keep An Eye OnFebruary 14th - MarketBeat
Promising Mid Cap Stocks To Add to Your WatchlistFebruary 16th - MarketBeat
The Rise of Recursion Pharmaceuticals: A Biotech Stock on the Move - RagingBull
Promising Biotech Stocks To Follow NowFebruary 17th - MarketBeat
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week - MSN
SoftBank reports new stakes in PacBio, Recursion Pharmaceuticals - MSN
Recursion Pharmaceuticals (NASDAQ: RXRX) Surges Nearly 24% as Nvidia Retains Stake – market - HPBL
Recursion Pharmaceuticals Stock Soars as Nvidia Maintains Stake – A Vote of Confidence? – market - HPBL
Recursion Pharmaceuticals (RXRX) Sees Institutional Investors Adjust Positions Amid Market Volatility - HPBL
Institutional Investors Bet Big on Recursion Pharmaceuticals (RXRX) Amid Growing Biotech Interest - HPBL
Why Recursion Pharmaceuticals (RXRX) Skyrocketed 23.88% on Friday – market - HPBL
Recursion Pharmaceuticals (RXRX): A Biotech Stock Outpacing the Market with Explosive Growth - HPBL
Recursion Pharmaceuticals (RXRX) Stock Surges 15%: Nvidia’s Vote of Confidence Sparks AI Biotech Rally - HPBL
Recursion Pharmaceuticals Stock Surges 15.8% as Nvidia Retains Stake – market - HPBL
Mirae Asset Global Investments Co. Ltd. Sells 74,818 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Shares of 10 Firms Soar on Friday - Insider Monkey
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 8.6%What's Next? - MarketBeat
Why Recursion Pharmaceuticals Inc. (RXRX) Soared on Friday? - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.6% HigherWhat's Next? - MarketBeat
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why - MSN
Best Mid Cap Stocks To Follow TodayFebruary 14th - MarketBeat
Why Recursion Pharmaceuticals Stock Is Soaring Today - MSN
Best Pharmaceutical Stocks To Watch NowFebruary 14th - MarketBeat
Cathie Wood Doubles Down on 3D Systems, Blade Air Mobility, and Recursion Pharmaceuticals: Key Moves for Ark Invest – market - HPBL
SoftBank Latest Moves: Major Stakes in PacBio, Recursion Pharmaceuticals and Better Home & Finance - HPBL
Recursion Pharmaceuticals (RXRX) Stock Soars 15.8%, Nvidia Confidence Boosts Investor Sentiment - HPBL
Recursion Pharmaceuticals Soars 15.8% Amid Nvidia Confidence Boost – market - HPBL
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리커젼 파마 주식 (RXRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Chief Executive Officer |
Feb 05 '25 |
Sale |
7.68 |
20,000 |
153,600 |
1,273,156 |
0.27%
3.05%
자본화:
|
볼륨(24시간):